Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels

Metabolism: Clinical and Experimental

Volumn 46, Issue 4, 1997, Pages 355-358

  Tanaka, Kouichi ^a   Hayashi, Kozo ^a   Shingu, Tetsuji ^a   Kuga, Yoshio ^a   Okura, Yoshifumi ^a   Yasunobu, Yuji ^a   Ohtani, Harumi ^a   Nomura, Shuichi ^a   Kurushima, Hitoshi ^a   Saeki, Masayumi ^a   Kambe, Masayuki ^a   Kajiyama, Goro ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICERITROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 12644304233     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90046-9     Document Type: Article

References (39)

1. Berg K: A new serum type system in man: The Lp-system. Acta Pathol Microbiol Scand 59:369-382, 1963
2. Berg K, Dahlen G, Frick MH: Lp(a) lipoprotein and pre-β-lipoprotein in patients with coronary heart disease, Clin Genet 6:230-235, 1974
3. Dahlen GH, Guyton JR, Attar M, et al: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74:758-765, 1986
4. Genest J Jr, McNamara JR, Ordovas JM, et al: Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 19:792-802, 1992
5. Hoefler G, Harnoncourt F, Paschke E, et al: Lipoprotein (a): A risk factor for myocardial infarction. Arteriosclerosis 8:398-401, 1988
6. Rosengren A, Wilhelmsen L, Erikssen E, et al: Lipoprotein(a) and coronary heart disease: A prospective study in a general population sample of middle aged men. Br Med J 301:1248-1251, 1990
7. Murai A, Miyahara T, Fujimoto N, et al: Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 59:199-204, 1986
8. Zenker G, Koeltringer P, Bone G, et al: Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 17:942-945, 1986
9. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993
10. Boerwinkle E, Leffert CC, Lin J, et al: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90:52-60, 1992
11. Krempler F, Kostner GM, Bolzano K, et al: Turnover of lipoprotein(a) in man. J Clin Invest 65:1483-1490, 1980
12. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226:271-276, 1989
13. Nakahara H, Nakanishi T, Uyama O, et al: Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Ren Fail 15:189-193, 1993
14. Matsunaga A, Handa K, Mori T, et al: Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis 94:241-248, 1992
15. The Expert Panel: Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-69, 1988
16. Hayahsi K, Ohtani H, Okura Y, et al: Hypolipidemic effect of beraprost sodium in patients with arteriosclerosis obliterans accompanied by hyperlipidemia. Curr Ther Res 55:1486-1491, 1994
17. Utermann G: The mysteries of lipoprotein(a). Science 246:904-910, 1989
18. Scanu AM, Fless GM: Lipoprotein(a): Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990
19. Sommer A, Gorges R, Kostner GM, et al: Sulfhydryl-selective fluorescence labeling of lipoprotein(a) reveals evidence for one single disulfide linkage between apoprotein(a) and B-100. Biochemistry 30:11245-11249, 1991
20. McLean JW, Tomlison JE, Kuang WJ, et al: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330:132-137, 1987
21. Hajjar KA, Gavish D, Breslow JL, et al: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303-305, 1989
22. Lascalzo J, Weinfield M, Fless GM, et al: Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10:240-245, 1990
23. Kostner GM, Avogaro P, Cazzolalo G, et al: Lipoprotein Lp(a) and risk for myocardial infarction. Atherosclerosis 38:51-61, 1981
24. Molgaard J, Klausen IC, Lassvik C, et al: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12:895-901, 1992
25. Schreiner PJ, Morrisett JD, Sharrett AR, et al: Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 13:826-833, 1993
26. Alber JJ, Canaba VG, Warnick GR, et al: Lp(a) lipoprotein: Relation to sinking pre-b lipoprotein, hyperlipoproteinemia and apolipoprotein B. Metabolism 24:1047-1054, 1975
27. Vessby B, Kostner G, Lithell H, et al: Diverging effects of cholestyramine on apolipoprotein B and lipoprotein(a). Atherosclerosis 44:61-71, 1982
28. Kostner GM, Gavish D, Leopold B, et al: HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80:1313-1319, 1989
29. Maeda S, Okuno M, Abe A, et al: Lack of effect of probucol on serum lipoprotein(a) levels. Atherosclerosis 79:267-269, 1989
30. Vaelimaeki M, Laitinen K, Ylikahrit R, et al: The effect of moderate alcohol intake on apolipoprotein A-I-containing lipoproteins and lipoprotein(a). Metabolism 40:1168-1172, 1991
31. Gurakar A, Hoeg JM, Kostner G, et al: Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 57:293-301, 1985
32. Noma A, Maeda S, Okuno M, et al: Reduction of serum lipoprotein(a) levels in hyperlipidemic patients with a-tocopheryl nicotinate. Atherosclerosis 84:213-217, 1990
33. Gavish D, Brewer JL: Lipoprotein reduction by N-acetylcysteine. Lancet 337:203-204, 1991
34. Alber JJ, Taggart HM, Applebaum-Bowden D, et al: Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with anabolic steroid stanozolon. Biochim Biophys Acta 795:293-303, 1984
35. Sano R, Fujino A, Saito T, et al: Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients with coronary artery disease. Tohoku J Exp Med 169:299-307, 1993
36. Svedmyr N, Harthon L: Comparison between the absorption of nicotinic acid and pentaerythritol tetranicotinate (Perycit®) from ordinary and enterocoated tablets. Acta Pharmacol Toxicol 28:66-74, 1970
37. Kazumi T, Yoshino G, Maeda T, et al: Effects of niceritrol on elevated serum lipoprotein Lp(a) levels in diabetic patients with or without overt proteinuria. Curr Ther Res 55:546-551, 1994
38. Segawa J, Sadayasu T, Nomura S, et al: Effects of niceritrol on plasma Lp(a) and fibrinolytic system. Eur Heart J 13:195, 1992 (abstr, suppl)
39. Kazumi T, Yoshino G, Shima F, et al: Niceritrol-induced reductions in serum lipoprotein(a) continue for one year. Curr Ther Res 54:550-552, 1993